RPRX Royalty Pharma plc

  1. Stocks
  2. Healthcare
  3. NASDAQ: RPRX

Price (delayed)

$28.16

Market cap

$16.82B

P/E Ratio

11.09

Dividend/share

$0.81

EPS

$2.54

Enterprise value

$22.48B

Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals ...

Highlights
The P/E is 76% lower than the last 4 quarters average of 46.3
Royalty Pharma's debt has decreased by 14% YoY
The company's quick ratio fell by 42% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.royaltypharma.com
Peers: ANIP ABT LLY

Key stats

What are the main financial stats of RPRX
Market
Shares outstanding
597.43M
Market cap
$16.82B
Enterprise value
$22.48B
Valuations
Price to earnings (P/E)
11.09
Price to book (P/B)
1.67
Price to sales (P/S)
5.35
EV/EBIT
17.01
EV/EBITDA
17.01
EV/Sales
9.55
Earnings
Revenue
$2.35B
EBIT
$1.32B
EBITDA
$1.32B
Free cash flow
$2.98B
Per share
EPS
$2.54
Free cash flow per share
$6.65
Book value per share
$16.88
Revenue per share
$5.26
TBVPS
$36.6
Balance sheet
Total assets
$16.38B
Total liabilities
$6.3B
Debt
$6.14B
Equity
$10.08B
Working capital
$1.11B
Liquidity
Debt to equity
0.61
Current ratio
7.9
Quick ratio
7.87
Net debt/EBITDA
4.28
Margins
EBITDA margin
56.1%
Gross margin
100%
Net margin
48.2%
Operating margin
63.4%
Efficiency
Return on assets
6.8%
Return on equity
11.5%
Return on invested capital
6.2%
Return on capital employed
8.2%
Return on sales
56.1%
Dividend
Dividend yield
2.88%
DPS
$0.81
Payout ratio
31.9%

RPRX stock price

How has the Royalty Pharma stock price performed over time
Intraday
0.97%
1 week
-0.21%
1 month
-6.69%
1 year
-22.3%
YTD
0.25%
QTD
-7.28%

Financial performance

How have Royalty Pharma's revenue and profit performed over time
Revenue
$2.35B
Gross profit
$2.35B
Operating income
$1.49B
Net income
$1.13B
Gross margin
100%
Net margin
48.2%
The revenue has increased by 5% YoY
Royalty Pharma's gross profit has increased by 5% YoY

Growth

What is Royalty Pharma's growth rate over time

Valuation

What is Royalty Pharma stock price valuation
RPRX P/E details
P/E
11.09
P/B
1.67
P/S
5.35
EV/EBIT
17.01
EV/EBITDA
17.01
EV/Sales
9.55
The P/E is 76% lower than the last 4 quarters average of 46.3
RPRX's P/B is 12% below its last 4 quarters average of 1.9
RPRX's equity is up by 6% year-on-year and by 5% since the previous quarter
The P/S is 8% below the last 4 quarters average of 5.8
The revenue has increased by 5% YoY

Efficiency

How efficient is Royalty Pharma business performance

Dividends

What is RPRX's dividend history
Dividend details
DPS
$0.81
Dividend yield
2.88%
Payout ratio
31.9%
Recent dividends

Financial health

How did Royalty Pharma financials performed over time
Royalty Pharma's total assets is 160% more than its total liabilities
The current ratio has declined by 42% since the previous quarter
The company's quick ratio fell by 42% QoQ
Royalty Pharma's debt is 39% lower than its equity
The debt to equity has decreased by 19% YoY and by 4.7% QoQ
Royalty Pharma's debt has decreased by 14% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.